In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.
Almyroudis
Nikolaos G
NG
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Sutton
Deanna A
DA
Fothergill
Annette W
AW
Rinaldi
Michael G
MG
Kusne
Shimon
S
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D054714:Echinocandins; D015725:Fluconazole / Q000627:therapeutic use; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D017964:Itraconazole / Q000627:therapeutic use; D007654:Ketoconazole / Q000627:therapeutic use; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D009091:Mucormycosis / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine; D000077336:Caspofungin; D065819:Voriconazole; D007654:Ketoconazole